Innate Pharma Welcomes Jonathan Dickinson as New CEO and Chairman of Executive Board

Innate Pharma SA, a leading biotech company, has announced the appointment of Jonathan Dickinson as its new Chief Executive Officer (CEO) and Chairman of the Executive Board, starting November 1, 2024. Dickinson, who will be stepping into the role previously held on an interim basis by Dr. Hervé Brailly, co-founder of Innate, brings a wealth of experience and strategic leadership to the company.

Most recently, Dickinson was Executive Vice President and General Manager for Europe at Incyte, a position he held since 2016. His career has also included senior leadership roles at ARIAD Pharmaceuticals, a US biotech specializing in oncology, and at Bristol-Myers Squibb. Prior to this, he spent 13 years at Hoffmann-La Roche, where he played a pivotal role in advancing the company’s oncology portfolio. 

Dickinson began his career at Novartis, where he held various roles of increasing responsibility within the oncology and endocrinology departments. He holds a Bachelor’s degree in Genetics and an MBA from the University of Nottingham. Dr. Brailly will continue with the company in an advisory capacity for the coming months to ensure a smooth transition. Additionally, the Board plans to propose Dr. Brailly for a Board seat at the next available opportunity.

Irina Staatz-Granzer, Chairwoman of the Supervisory Board, mentioned “I am very pleased to announce the appointment of Jonathan Dickinson as our new Chief Executive Officer. Jonathan is a distinguished industry leader whose extensive experience in the biotechnology and pharmaceutical sectors, combined with his proven leadership abilities, make him the ideal choice to lead Innate Pharma. We are confident that his vision and strategic acumen will drive the advancement of our innovative immuno-oncology pipeline and position the Company for continued success in the next phase of its growth.”

Jonathan Dickinson, new Chief Executive Officer of Innate Pharma, said in a statement, “I am excited to join Innate Pharma, a pioneer in harnessing the power of the immune system to fight cancer, at a pivotal moment in the Company’s evolution. With a diverse pipeline spanning early-stage ADCs and ANKET® NK-cell engagers to more advanced programs like lacutamab and monalizumab, I look forward to working with the talented team at Innate to drive the Company’s innovative therapies forward. Together, we will continue to advance Innate Pharma’s mission to deliver transformative treatments for patients while creating value for employees, shareholders, and all our stakeholders.”